Myeloproliferative Diseases

This page contains recent news articles, when available, and an overview of Myeloproliferative Diseases but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Myeloproliferative Diseases

Beacon NewsFlashes – November 3, 2009  -  ‎Nov 3, 2009‎
The MDS Beacon5th International Congress On Myeloproliferative Diseases And Myelodysplastic Syndromes — On November 5 through 7, the 5th International Congress on ...

Incyte Corporation Q3 2009 Earnings Call Transcript  -  ‎Nov 5, 2009‎
Seeking Alpha (blog)Group at the NCI to evaluate 424 in children with relapsed or refractory solid tumors, haematologic malignancies, and myeloproliferative diseases. ...

Malattie mieloproliferative Barbui unico europeo a New York  -  ‎Nov 3, 2009‎
L'Eco di Bergamo...che interverranno al quinto International Patient Symposium on Myeloproliferative Diseases che si terrà mercoledì 4 novembre a New York. ...

Novel Tumor Suppressor Discovered  -  ‎Aug 3, 2009‎
Science Daily (press release)Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid

Incyte Corporation Q2 2009 Earnings Call Transcript  -  ‎Jul 30, 2009‎
Seeking AlphaFor 424's use in the other two myeloproliferative diseases, polycythemia vera and essential thrombocythemia, we have about 70 patients enrolled in an

Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates ...  -  Dec 6, 2008
WELT ONLINE,Myeloproliferative diseases (MPDs) are a related group of hematological neoplasms characterized by dysfunction of the bone marrow resulting in either over

Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting  -  Dec 7, 2008
WELT ONLINE,Mutational activation of JAK2 is observed in the majority of patients with myeloproliferative diseases including polycythemia vera,

Glivec Receives US Approval As First Treatment To Reduce Risk Of ...  -  Dec 26, 2008
Medical News Today (press release),Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

Imatinib Okayed by FDA for GIST Recurrence  -  Dec 22, 2008
MedPage Today,It is also approved for myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements,

Hugin-News: Novartis International AG (english)  -  Dec 19, 2008
N24 Börse,Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

More than 200 abstracts at ASH and SABCS reveal potential ...  -  Dec 3, 2008
Trading Markets (press release),Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

Novartis International AG (VTX:NOVN) Tasigna® Demonstrates Rapid ...  -  Dec 11, 2008
ABN Newswire (press release),Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

Data Shows Longest Ever Survival for Patients With Life ...  -  Dec 8, 2008
ITNews,Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

SuperGen, Inc. (F3Q08) Earnings Conference Call Transcript  -  Nov 4, 2008
Seeking Alpha,Notably, it inhibits the V617F mutants of JAK2, a protein that place a causal role in myeloproliferative diseases. In addition, SGI-1252 avoids the immune

Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical ...  -  Oct 26, 2008
Earthtimes (press release),Pathways triggered by the JAKs are dysregulated in inflammation, myeloproliferative diseases, and other liquid and solid cancers. INCB18424 is Incyte’s lead

Incyte Reports Progress in Multiple Clinical Programs Announces ...  -  Nov 6, 2008
Genetic Engineering News (press release),INCB18424: Additional Myeloproliferative Diseases: Polycythemia Vera (PV) and Essential Thrombocythemia (ET) -- Ongoing enrollment and site initiation of an

Use Of Radioactive Radium-224 In Therapy Discontinued Due To ...  -  Jun 24, 2008
Medical News Today (press release),1950 are responsible for the elevated appearance of myeloproliferative diseases in the exposed group observed here," commented Dr. Roland R. Wick.

Higher Initial Dose of Glivec Achieved Better Early Responses Than ...  -  Jun 15, 2008
PharmaLive.com (press release),Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in ...  -  Jun 13, 2008
Centre Daily Times,Pathways triggered by the JAKs are dysregulated in inflammation, myeloproliferative diseases, and other liquid and solid cancers. INCB18424 is Incyte's lead

DJ HUGIN NEWS/Higher initial dose of Glivec achieved better early ...  -  Jun 13, 2008
Ad-Hoc-News (Pressemitteilung),Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

A Review of Articles From Last Month's Archives of Pathology ...  -  May 15, 2008
RedOrbit,...myeloid leukemia from reactive leukocytosis and other myeloproliferative diseases due to cytogenetic and/or molecular testing of peripheral blood 2.

Launch of Highly Targeted Cancer Treatment Tasigna(R) (Nilotinib ...  -  May 20, 2008
RedOrbit,Glivec(R) is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec(R) is also approved for

Seattle Genetics Initiates SGN-33 Clinical Trial in Combination ...  -  Mar 20, 2008
Earthtimes,Stable disease was observed in six out of ten patients with MDS and in two out of four patients with other myeloproliferative diseases.

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 ...  -  Dec 6, 2007
ReutersIn preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce V617F expressing cell populations in a

Data Presented At The American Society Of Hematology 49th Meeting ...  -  Dec 16, 2007
PR-USA.net (press release),Myeloproliferative diseases (MPDs) are a related group of hematological neoplasms characterized by dysfunction of the bone marrow resulting in either over

Seattle Genetics Reports Multiple Complete Remissions With SGN-33 ...  -  Dec 10, 2007
WELT ONLINE,Stable disease was observed in six out of ten patients with MDS and in two out of four patients with other myeloproliferative diseases.

Rigel Announces Presentations at the 2007 American Society of ...  -  Dec 5, 2007
PR Newswire (press release),2007 5:30 pm - 7:30 pm Session Name -- ITP, TTP and HIT Poster #464 Targeting myeloproliferative diseases with JAK2 inhibitors Monday, December 10,

Otsuka Pharmaceutical Acquires Rights to IV Busulfex from PDL ...  -  Dec 17, 2007
CNNMoney.comAbout 70 percent of the allogenic transplants are for leukemia and myeloproliferative diseases. WARNING: Busulfex (busulfan) Injection is a potent cytotoxic

Tasigna(R) gains European approval for patients with a life ...  -  Nov 27, 2007
CNNMoney.comGlivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for

Top Scientists to Receive Prestigious Awards From the American ...  -  Dec 5, 2007
Earthtimes,Dr. Vainchenker will be recognized for his research on the genetic basis of myeloproliferative diseases, which result in an overproduction of blood cells in

tasigna(r) receives us approval providing new hope to chronic ...  -  Oct 29, 2007
CNNMoney.com...is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (mds/mpd). glivec is also approved for hypereosinophilic

tasigna® receives us approval  -  Oct 29, 2007
Ad-Hoc-News (Pressemitteilung),...ofpatients with myelodysplastic/myeloproliferative diseases (mds/mpd).glivec is also approved for hypereosinophilic syndrome and/or chroniceosinophilic

exelixis q3 2007 earnings call transcript  -  Nov 5, 2007
Seeking Alpha,...an important kinase that appears to drive a variety of myeloproliferative diseases when present in a mutationally activated form. we have exhaustively

Incyte Receives $10 million from the Sale of a Convertible ...  -  Oct 10, 2007
PR-Inside.com (Pressemitteilung),These include a Phase II CCR5 antagonist for HIV, a Phase II JAK inhibitor that is being initially developed as a treatment for myeloproliferative diseases,

Support groups  -  Sep 30, 2007
The Huntsville Times - al.com,...lymphoma or multiple myeloma and other myeloproliferative diseases, The Center for Cancer Care, 1 Hospital Drive, Oct. 2, 6 pm, 205-989-0098.



Background information on Myeloproliferative Diseases [When available]

The myeloproliferative diseases are a group of diseases of the bone marrow where excess cells are produced. The delineation from leukemia is artificial, although the myeloproliferative diseases on the whole have a much better prognosis than the leukemias. The concept was first proposed in 1951 by the eminent hematologist William Dameshek.

The myeloproliferative diseases are:
  • Chronic myelogenous leukemia (CML)
  • Polycythemia vera (PCV)
  • Essential thrombocytosis (ET)
  • Myelofibrosis (increased connective tissue with decreased room for production of normal blood cells).
All MPDs arise from precursors of the "myeloid" lineage in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).

Search the web for more resources on Myeloproliferative Diseases



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy